Market Closed -
Canadian Securities Exchange
03:39:42 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
0.025
CAD
|
+25.00%
|
|
-.--%
|
-80.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
661.6
|
230.9
|
113.7
|
70.9
|
50.7
|
Enterprise Value (EV)
1 |
449.1
|
224.4
|
148.8
|
100.1
|
90.74
|
P/E ratio
|
-12
x
|
-1.06
x
|
-0.48
x
|
-1.24
x
|
-0.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
352,080,895
x
|
21,077,843
x
|
5,287,793
x
|
2,344,344
x
|
1,027,432
x
|
EV / Revenue
|
239,015,966
x
|
20,476,310
x
|
6,921,336
x
|
3,309,722
x
|
1,838,642
x
|
EV / EBITDA
|
-10.7
x
|
-3.47
x
|
-4.19
x
|
-6.42
x
|
-3.84
x
|
EV / FCF
|
-3.08
x
|
-1.18
x
|
-1.68
x
|
-2.59
x
|
-2.7
x
|
FCF Yield
|
-32.4%
|
-84.9%
|
-59.4%
|
-38.5%
|
-37.1%
|
Price to Book
|
1.61
x
|
0.87
x
|
0.81
x
|
0.52
x
|
0.3
x
|
Nbr of stocks (in thousands)
|
26,893
|
30,793
|
48,366
|
74,627
|
153,651
|
Reference price
2 |
24.60
|
7.500
|
2.350
|
0.9500
|
0.3300
|
Announcement Date
|
3/19/19
|
3/10/20
|
3/9/21
|
4/5/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
1.879
|
10.96
|
21.5
|
30.24
|
49.35
|
EBITDA
1 |
-14.73
|
-42.1
|
-64.73
|
-35.5
|
-15.6
|
-23.66
|
EBIT
1 |
-15.19
|
-43.16
|
-68.42
|
-41.85
|
-28.36
|
-31.57
|
Operating Margin
|
-
|
-2,296.7%
|
-624.47%
|
-194.68%
|
-93.77%
|
-63.98%
|
Earnings before Tax (EBT)
1 |
-15.01
|
-45.55
|
-196.4
|
-183.4
|
-39.98
|
-36.36
|
Net income
1 |
-13.46
|
-45.2
|
-195.2
|
-182.5
|
-42.14
|
-35.5
|
Net margin
|
-
|
-2,405.69%
|
-1,781.1%
|
-849.23%
|
-139.34%
|
-71.94%
|
EPS
2 |
-1.196
|
-2.055
|
-7.075
|
-4.938
|
-0.7632
|
-0.4103
|
Free Cash Flow
1 |
-5.676
|
-145.7
|
-190.6
|
-88.36
|
-38.58
|
-33.64
|
FCF margin
|
-
|
-7,755.1%
|
-1,739.46%
|
-411.06%
|
-127.57%
|
-68.16%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/20/18
|
3/19/19
|
3/10/20
|
3/9/21
|
4/5/22
|
4/28/23
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
1 |
9.522
|
7.28
|
9.466
|
10.58
|
11.63
|
9.922
|
17.23
|
24.1
|
EBITDA
1 |
-3.995
|
-4.773
|
-3.017
|
-2.237
|
-4.274
|
-5.54
|
-16.97
|
-3.904
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18.28
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-75.84%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/11/21
|
11/24/21
|
4/5/22
|
5/25/22
|
8/29/22
|
11/23/22
|
4/28/23
|
5/30/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
35.1
|
29.2
|
40
|
Net Cash position
1 |
63.7
|
212
|
6.59
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.9892
x
|
-1.871
x
|
-1.692
x
|
Free Cash Flow
1 |
-5.68
|
-146
|
-191
|
-88.4
|
-38.6
|
-33.6
|
ROE (net income / shareholders' equity)
|
-30.8%
|
-18.4%
|
-57.5%
|
-89.9%
|
-28.6%
|
-23.1%
|
ROA (Net income/ Total Assets)
|
-16.9%
|
-9.94%
|
-10.8%
|
-9.45%
|
-8.73%
|
-8.42%
|
Assets
1 |
79.64
|
455
|
1,801
|
1,932
|
482.6
|
421.7
|
Book Value Per Share
2 |
5.420
|
15.30
|
8.570
|
2.900
|
1.840
|
1.090
|
Cash Flow per Share
2 |
4.470
|
7.910
|
0.8800
|
0.2300
|
0.0500
|
0.0300
|
Capex
1 |
6.75
|
81.6
|
220
|
50.3
|
9.12
|
1.12
|
Capex / Sales
|
-
|
4,344.39%
|
2,004.69%
|
233.82%
|
30.16%
|
2.28%
|
Announcement Date
|
4/20/18
|
3/19/19
|
3/10/20
|
3/9/21
|
4/5/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -80.00% | 4.97M | | +27.19% | 5.56B | | -33.59% | 3.52B | | -2.97% | 3.01B | | -24.21% | 2.65B | | -10.11% | 2.3B | | +43.66% | 1.91B | | +46.15% | 1.5B | | -13.92% | 1.41B | | +41.90% | 1.37B |
Alternative Medicine
|